11170376001
Roche
Anti-Bromodeoxyuridine
from mouse IgG1 (clone: BMC9318)
Sinonimo/i:
anti-BrdU, antibody
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
Prodotti consigliati
Origine biologica
mouse
Livello qualitativo
Coniugato
unconjugated
Forma dell’anticorpo
purified immunoglobulin
Tipo di anticorpo
primary antibodies
Clone
BMC9318, monoclonal
Saggio
90% (HPLC and SDS-PAGE)
Forma fisica
solution
Confezionamento
pkg of 50 μg (500 μl)
Produttore/marchio commerciale
Roche
Isotipo
IgG1
Temperatura di conservazione
−20°C
Descrizione generale
Anti-Bromodeoxyuridine is a monoclonal antibody to 5-bromo-2′-deoxyuridine-5′-monophosphate.
Specificità
The antibody specifically binds to bromodeoxyuridine and crossreacts with iodouridine (10%). Anti-bromo-deoxyuridine does not crossreact with fluorodeoxy-uridine, nor with any endogenous cellular components such as thymidine or uridine.
Immunogeno
The epitope is apparently inside the DNA helix. DNA has to be denatured to ssDNA before antibody efficiently binds to DNA-BrdU.
Applicazioni
Anti-bromodeoxyuridine (Anti-BrdU) antibody is suitable for monitoring proliferating cells in blood, tissues, and tumors, as well as for determining BrdU incorporation on a single-cell level using:
- Flow cytometry
- Immunohistocytochemistry
- Cryosections
- Paraffin sections
Qualità
The antibody is ≥90% pure as determined by SDS-PAGE with Coomassie-blue staining, and by HPLC.
Specifiche
Preparation: BALB/c mice were immunized with a bromodeoxyuridine-bovine serum albumin conjugate. Lymphocytes isolated from the spleen were fused with Ag8.653 myeloma cells to create the BMC 9318 clone. The antibody was produced in ascites in BALB/c mice and purified by ion-exchange chromatography.
No. of tests: 250 (Flow cytometry)
No. of tests: 250 (Flow cytometry)
Stato fisico
Solution, stabilized with phosphate buffered saline, pH 7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) gelatin.
Nota sulla preparazione
Working concentration: Flow cytometry: 2 μg/ml (0.2 μg/100 μl/106 cells); Immunohistocytochemistry: 6 μg/ml
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Risultati analitici
Anti-Bromodeoxyuridine shows 10% cross reaction with iodo-deoxyuridine, but no cross reaction to fluoro-deoxyuridine.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
Altre note
For life science research only. Not for use in diagnostic procedures.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
12 - Non Combustible Liquids
Classe di pericolosità dell'acqua (WGK)
nwg
Punto d’infiammabilità (°F)
No data available
Punto d’infiammabilità (°C)
No data available
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Derek C Adams et al.
American journal of physiology. Renal physiology, 297(3), F809-F815 (2009-06-19)
Long-term pulse chase experiments previously identified a sizable population of BrdU-retaining cells within the renal papilla. The origin of these cells has been unclear, and in this work we test the hypothesis that they become quiescent early during the course
Wouter Laurentius Smit et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(41), 25560-25570 (2020-09-30)
Deregulated global mRNA translation is an emerging feature of cancer cells. Oncogenic transformation in colorectal cancer (CRC) is driven by mutations in APC, KRAS, SMAD4, and TP53, known as the adenoma-carcinoma sequence (ACS). Here we introduce each of these driver
Erika A Correll et al.
IBRO neuroscience reports, 10, 31-41 (2021-04-17)
It has been demonstrated that adult born granule cells are generated after traumatic brain injury (TBI). There is evidence that these newly generated neurons are aberrant and are poised to contribute to poor cognitive function after TBI. Yet, there is
Xuexiao Li et al.
Cell death discovery, 8(1), 323-323 (2022-07-17)
Myelodysplastic syndromes (MDS) are characterized by daunting genetic heterogeneity and a high risk of leukemic transformation, which presents great challenges for clinical treatment. To identify new chemicals for MDS, we screened a panel of FDA-approved drugs and verified the neutrophil
Victoria Sofía Berenice Wies Mancini et al.
Glia, 67(2), 291-308 (2018-11-21)
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young people with very few therapeutic options available for its progressive forms. Its pathophysiology involves demyelination and neurodegeneration apparently driven by microglial activation, which is physiologically
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.